113 related articles for article (PubMed ID: 22166275)
21. First-trimester or second-trimester screening, or both, for Down's syndrome.
Malone FD; Canick JA; Ball RH; Nyberg DA; Comstock CH; Bukowski R; Berkowitz RL; Gross SJ; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Dukes K; Bianchi DW; Rudnicka AR; Hackshaw AK; Lambert-Messerlian G; Wald NJ; D'Alton ME;
N Engl J Med; 2005 Nov; 353(19):2001-11. PubMed ID: 16282175
[TBL] [Abstract][Full Text] [Related]
22. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
[TBL] [Abstract][Full Text] [Related]
23. Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha-fetoprotein, hCG, and unconjugated estriol: a prospective 2-year study.
Phillips OP; Elias S; Shulman LP; Andersen RN; Morgan CD; Simpson JL
Obstet Gynecol; 1992 Sep; 80(3 Pt 1):353-8. PubMed ID: 1379701
[TBL] [Abstract][Full Text] [Related]
24. Biochemical screening for chromosomal disorders and neural tube defects (NTD): is adjustment of maternal alpha-fetoprotein (AFP) still appropriate in insulin-dependent diabetes mellitus (IDDM)?
Sancken U; Bartels I
Prenat Diagn; 2001 May; 21(5):383-6. PubMed ID: 11360279
[TBL] [Abstract][Full Text] [Related]
25. Down syndrome maternal serum screening in patients with renal disease.
Benachi A; Dreux S; Kaddioui-Maalej S; Czerkiewicz I; Fakhouri F; Thervet E; Muller F
Am J Obstet Gynecol; 2010 Jul; 203(1):60.e1-4. PubMed ID: 20417486
[TBL] [Abstract][Full Text] [Related]
26. Maternal serum screening of Palestinian women in the West Bank.
Husseini A; Akkawi M
East Mediterr Health J; 2005 Jul; 11(4):824-7. PubMed ID: 16700399
[TBL] [Abstract][Full Text] [Related]
27. Maternal serum screening for aneuploid pregnancy by alpha-fetoprotein, hCG, and unconjugated estriol.
Heyl PS; Miller W; Canick JA
Obstet Gynecol; 1990 Dec; 76(6):1025-31. PubMed ID: 1700348
[TBL] [Abstract][Full Text] [Related]
28. Risk of Severe Maternal Morbidity or Death in Relation to Prenatal Biochemical Screening: Population-Based Cohort Study.
Lentz EJM; Park AL; Langlois AWR; Huang T; Meschino WS; Ray JG
Am J Perinatol; 2021 Jan; 38(1):44-59. PubMed ID: 31412403
[TBL] [Abstract][Full Text] [Related]
29. A prospective evaluation of a second-trimester screening test for fetal Down syndrome using maternal serum alpha-fetoprotein, hCG, and unconjugated estriol.
Cheng EY; Luthy DA; Zebelman AM; Williams MA; Lieppman RE; Hickok DE
Obstet Gynecol; 1993 Jan; 81(1):72-7. PubMed ID: 7677967
[TBL] [Abstract][Full Text] [Related]
30. First trimester biochemical screening for trisomy 21: the role of free beta hCG, alpha fetoprotein and pregnancy associated plasma protein A.
Spencer K; Aitken DA; Crossley JA; McCaw G; Berry E; Anderson R; Connor JM; Macri JN
Ann Clin Biochem; 1994 Sep; 31 ( Pt 5)():447-54. PubMed ID: 7530437
[TBL] [Abstract][Full Text] [Related]
31. [Specificity of biochemical markers of pregnancy second trimester].
Salazar López R; Ibarra Gallardo AL; Iduma Meléndrez M; Leyva Bojórquez R
Ginecol Obstet Mex; 2007 Oct; 75(10):608-14. PubMed ID: 18800579
[TBL] [Abstract][Full Text] [Related]
32. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
[TBL] [Abstract][Full Text] [Related]
33. The effect of temporal variation in biochemical markers of trisomy 21 across the first and second trimesters of pregnancy on the estimation of individual patient-specific risks and detection rates for Down's syndrome.
Spencer K; Crossley JA; Aitken DA; Nix AB; Dunstan FD; Williams K
Ann Clin Biochem; 2003 May; 40(Pt 3):219-31. PubMed ID: 12803832
[TBL] [Abstract][Full Text] [Related]
34. 2nd-trimester maternal serum marker results are not altered by delayed analysis.
Feldman B; Dvorin E; Phillips T; Kramer RL; Johnson MP; Evans MI
Fetal Diagn Ther; 1998; 13(5):302-4. PubMed ID: 9813424
[TBL] [Abstract][Full Text] [Related]
35. Replacing Alpha-Fetoprotein With Alpha-Fetoprotein-L3 Increases the Sensitivity of Prenatal Screening for Trisomy 21.
Huai L; Leng J; Ma S; Huang F; Shen J; Ding Y
Am J Ther; 2016; 23(6):e1754-e1757. PubMed ID: 26938756
[TBL] [Abstract][Full Text] [Related]
36. Correlation of ultrasound findings and biochemical markers in the second trimester of pregnancy in fetuses with trisomy 21.
Souter VL; Nyberg DA; El-Bastawissi A; Zebelman A; Luthhardt F; Luthy DA
Prenat Diagn; 2002 Mar; 22(3):175-82. PubMed ID: 11920888
[TBL] [Abstract][Full Text] [Related]
37. First-trimester combined screening for trisomy 21 at 7-14 weeks' gestation.
Wright D; Spencer K; Kagan K K; Tørring N; Petersen OB; Christou A; Kallikas J; Nicolaides KH
Ultrasound Obstet Gynecol; 2010 Oct; 36(4):404-11. PubMed ID: 20658511
[TBL] [Abstract][Full Text] [Related]
38. Cigarette smoking and levels of maternal serum alpha-fetoprotein, unconjugated estriol, and hCG: impact on Down syndrome screening.
Palomaki GE; Knight GJ; Haddow JE; Canick JA; Wald NJ; Kennard A
Obstet Gynecol; 1993 May; 81(5 ( Pt 1)):675-8. PubMed ID: 7682315
[TBL] [Abstract][Full Text] [Related]
39. Effect of Hispanic ethnicity on interpretation of maternal serum screening.
Byrne JL; Waller DK; Rose E; Elias S
Fetal Diagn Ther; 1997; 12(2):102-6. PubMed ID: 9218951
[TBL] [Abstract][Full Text] [Related]
40. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO; Wright D; Maiz N; Pandeva I; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Sep; 32(4):488-92. PubMed ID: 18726925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
